May 1, 2008 - The clinical impact of the first-ever prohealing stent, OrbusNeich's Genous Bio-engineered R stent, is the subject of a symposium at next month's 16th Annual Scientific Congress of the Hong Kong College of Cardiology.
Federico Piscione, M.D., of Federico II University, Naples, will present the latest clinical update on the Genous technology at the conference.
"Based on the data we've seen with the real-world use of Genous and in recent clinical trials, we believe that the stent is an important alternative to drug-eluting stents," said the symposium's chairperson, Tak Fu Tse, M.D., of the Hong Kong Sanatorium and Hospital, Hong Kong. "The stent's safety profile and the minimal requirements for dual antiplatelet therapy following placement can have a significant clinical impact, especially in patients who are likely to bleed or require surgery in the near future."
Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.
For more information: www.OrbusNeich.com
October 16, 2024 
